BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32505087)

  • 1. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
    Liu J; Gong Y; Shi J; Hao X; Wang Y; Zhou Y; Hou Y; Liu Y; Ding S; Chen Y
    Eur J Med Chem; 2020 May; 194():112244. PubMed ID: 32224380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
    Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
    Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
    Liao W; Hu G; Guo Z; Sun D; Zhang L; Bu Y; Li Y; Liu Y; Gong P
    Bioorg Med Chem; 2015 Aug; 23(15):4410-4422. PubMed ID: 26169763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.
    Megally Abdo NY; Milad Mohareb R; Halim PA
    Bioorg Chem; 2020 Apr; 97():103667. PubMed ID: 32087416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
    El-Wakil MH; Teleb M
    Bioorg Chem; 2021 Nov; 116():105304. PubMed ID: 34534756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
    Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
    Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Zhou S; Ren J; Liu M; Ren L; Liu Y; Gong P
    Bioorg Chem; 2014 Dec; 57():30-42. PubMed ID: 25173590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors.
    Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X
    Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.
    Liu J; Nie M; Wang Y; Hu J; Zhang F; Gao Y; Liu Y; Gong P
    Eur J Med Chem; 2016 Nov; 123():431-446. PubMed ID: 27490023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.